Ando Yuki, Hamasaki Toshimitsu
Office of New Drug II, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.
Pharm Stat. 2010 Jul-Sep;9(3):190-200. doi: 10.1002/pst.448.
The multi-regional clinical trials (MRCTs) being administered in different regions of the world now play a major role in providing evidence for the efficacy and safety of new drugs amidst the simultaneous global development and worldwide registration of such drugs, in support of the expeditious availability of medical products to patients. However, such trials present considerable challenges as far as quality, design, implementation, analysis, and interpretation are concerned. In this article, we share our observations and lessons learned from the design, implementation, analysis, and interpretation of some MRCTs with case examples. Current Japanese regulatory guidance on MRCTs is introduced along with some suggestions for design, implementation, and interpretation.
目前在世界不同地区开展的多区域临床试验(MRCTs),在全球同步开展新药研发及全球注册以支持医疗产品尽快惠及患者的过程中,为新药的疗效和安全性提供证据方面发挥着重要作用。然而,就质量、设计、实施、分析和解读而言,此类试验面临着相当大的挑战。在本文中,我们通过案例分享我们在一些多区域临床试验的设计、实施、分析和解读方面的观察结果和经验教训。同时介绍了日本目前关于多区域临床试验的监管指南以及一些关于设计、实施和解读的建议。